Rep. Josh Gottheimer Sells Off Sysmex Corporation ADR (OTCMKTS:SSMXY) Shares

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Sysmex Corporation ADR (OTCMKTS:SSMXY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Sysmex stock on December 5th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 12/17/2025.
• Sold $1,001 – $15,000 in shares of Cheniere Energy (NYSE:LNG) on 12/12/2025.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 12/11/2025.
• Sold $15,001 – $50,000 in shares of Air Products and Chemicals (NYSE:APD) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Utz Brands (NYSE:UTZ) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of CommVault Systems (NASDAQ:CVLT) on 12/5/2025.
• Sold $1,001 – $15,000 in shares of SEA (NYSE:SE) on 12/5/2025.
• Sold $1,001 – $15,000 in shares of Dassault Systemes (OTCMKTS:DASTY) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of Edwards Lifesciences (NYSE:EW) on 11/19/2025.

Sysmex Trading Down 1.3%

SSMXY opened at $9.96 on Friday. The stock has a market capitalization of $6.27 billion, a PE ratio of 19.92 and a beta of 1.13. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 2.49. Sysmex Corporation ADR has a 12-month low of $9.00 and a 12-month high of $20.31. The firm’s fifty day moving average price is $9.82 and its 200 day moving average price is $12.39.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $826.60 million for the quarter, compared to analyst estimates of $880.80 million. Sysmex had a return on equity of 9.86% and a net margin of 9.32%. As a group, research analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised shares of Sysmex from a “hold” rating to a “buy” rating in a report on Thursday, October 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.